The most important number in longevity | Martin Borch Jensen | TEDxBoston

Quick Overview

The most important number in longevity, according to Martin Borch Jensen, is not the chronological age but the biological age as determined by validated aging clocks, which can offer a more accurate measure of health and predict future outcomes, allowing for targeted interventions.

Key Points: Martin Borch Jensen states his biological age is 12, compared to his chronological age of 63, based on a test he took three times. He references a friend, a 25-year-old brilliant biologist, whose biological age test resulted in 12, suggesting the test results can be significantly different from chronological age. The speaker argues that $2 million, which could buy one person's optimal health for one year, could instead fund trust in age tests for everyone forever via a non-profit. He advocates for using validated, third-party tested aging clocks to measure the effectiveness of longevity interventions, rather than relying solely on chronological time. The speaker suggests that the current approach of predicting the past (like car mileage) with age tests is less useful than predicting the future (like how long a mouse will live) with these metrics. The goal is to use these clocks to benchmark interventions and see if they result in a slower aging process, which is more meaningful than just having fun with 'longevi-tainment'.

Context: Martin Borch Jensen presents at TEDxBoston to discuss the concept of biological age versus chronological age, emphasizing the need for reliable, standardized metrics to measure the success of longevity interventions. He uses personal anecdotes, including his own surprisingly young biological age result and that of a colleague, to illustrate the potential discrepancy between how old one is chronologically and how old their body is biologically.

Detailed Analysis

Martin Borch Jensen argues that chronological age is an insufficient metric for assessing health and longevity, introducing the concept of biological age measured by aging clocks. He shares that he is chronologically 63 but his biological age is 12, based on tests he took multiple times, contrasting this sharply with the friend who is 25 but biologically 12. Jensen points out the immense potential impact of the longevity field, framing a choice: $2 million could fund one person's optimal health for a year, or it could fund trust in age tests for everyone forever through a non-profit. He stresses the need for rigorous, third-party validated aging clocks, similar to how car reliability is tested. The ultimate goal, he asserts, is to use these validated clocks to measure whether longevity interventions—like those involving peptides from China or red light therapy stations—actually work by slowing the rate of aging, rather than just creating 'longevi-tainment.' He concludes by suggesting that we should allocate resources toward developing these reliable metrics so we can accurately assess which interventions lead to longer, healthier lives.